# Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Source: https://onco.cc/trials/nct01697384/  
OnCo record `nct01697384` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Histrelin in Prostate cancer, run by Endo USA Inc., a Keenova Therapeutics Company, completed.

## Summary

Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01697384 by Endo USA Inc., a Keenova Therapeutics Company, with 138 participants recorded, started 2000-04 and reaching its primary completion in 2003-08. Interventions recorded: histrelin acetate. Conditions recorded: Prostate Cancer, Adenocarcinoma of the Prostate.

Linked to the drug Histrelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01697384
- Phase: 3
- Setting: Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer
- Sponsor: Endo USA Inc., a Keenova Therapeutics Company
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT01697384: https://clinicaltrials.gov/study/NCT01697384

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Histrelin](https://onco.cc/drugs/histrelin/)
- companies: [Endo (now Keenova Therapeutics and Par Health)](https://onco.cc/companies/endo/)

---
JSON: https://onco.cc/api/v1/entities/nct01697384.json